Opendata, web and dolomites

NANOSTEM SIGNED

New nanomaterials for neural stem cells drug delivery

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 NANOSTEM project word cloud

Explore the words cloud of the NANOSTEM project. It provides you a very rough idea of what is the project "NANOSTEM" about.

efficacy    industrial    teams    strategy    differentiation    stroke    nscs    cells    nanoparticle    hypothesis    ranging    entrepreneurship    academic    wp3    regenerative    containing    packages    animal    modeling    pharmacology    neuroscience    hospital    computational    formulations    proliferation    regulation    biological    interdisciplinary    professional    neural    vitro    brings    scientific    cell    train    vivo    nanoparticles    synthesis    wp2    diseases    modern    complemented    groups    injuries    traumatic    permeation    nanobiotechnology    society    efficient    esrs    organic    polymer    complementary    tackle    differentiate    biology    transport    expertise    toxicity    wp    wp1    six    therapeutic    translation    skills    characterization    full    nanostem    models    neurodegenerative    migration    burden    training    mayor    total    neurons    personal    sciences    brain    seven    nanomaterials    pharmaceuticals    distributed    14    team    uploading    evaluation    therapeutics    substantial    union    chemistry    associate    bbb    nps    clinical    stem    combined   

Project "NANOSTEM" data sheet

The following table provides information about the project.

Coordinator
QUEEN MARY UNIVERSITY OF LONDON 

Organization address
address: 327 MILE END ROAD
city: LONDON
postcode: E1 4NS
website: http://www.qmul.ac.uk

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Total cost 3˙590˙354 €
 EC max contribution 3˙590˙354 € (100%)
 Programme 1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers)
 Code Call H2020-MSCA-ITN-2017
 Funding Scheme MSCA-ITN-ETN
 Starting year 2018
 Duration (year-month-day) from 2018-06-01   to  2022-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    QUEEN MARY UNIVERSITY OF LONDON UK (LONDON) coordinator 819˙863.00
2    CENTRO DE NEUROCIENCIAS E BIOLOGIACELULAR ASSOCIACAO PT (COIMBRA) participant 715˙069.00
3    UNIVERSITE D'ARTOIS FR (ARRAS) participant 525˙751.00
4    THE UNIVERSITY OF BIRMINGHAM UK (BIRMINGHAM) participant 273˙287.00
5    KAROLINSKA INSTITUTET SE (STOCKHOLM) participant 263˙659.00
6    UNIVERSITAET INNSBRUCK AT (INNSBRUCK) participant 255˙934.00
7    HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH DE (NEUHERBERG) participant 249˙216.00
8    MJR PHARMJET GMBH DE (UBERHERRM) participant 249˙216.00
9    CENTRO HOSPITALAR E UNIVERSITARIO DE COIMBRA E.P.E. PT (COIMBRA) participant 238˙356.00
10    THE UNIVERSITY OF WARWICK UK (COVENTRY) participant 0.00
11    BRAINS FOR BRAIN FOUNDATION ONLUS IT (PADOVA) partner 0.00
12    HCS-Pharma FR (LOOS) partner 0.00
13    UNIVERSIDADE DE COIMBRA PT (COIMBRA) partner 0.00
14    UNIVERSITAT DES SAARLANDES DE (SAARBRUCKEN) partner 0.00

Map

 Project objective

Brain conditions such as neurodegenerative diseases, stroke and traumatic injuries are a mayor burden in modern society. Because neural stem cells (NSCs) can differentiate into new neural cells including neurons, the regulation of their proliferation, differentiation and migration represent a promising regenerative/therapeutic strategy. The hypothesis of NanoStem project is that novel nanoparticles (NPs) combined with recent identified/developed pharmaceuticals can be an efficient approach to control the biological activity of NSCs. The scientific project is organized in three work packages (WP), each focusing on specific objectives and containing well-defined deliverables. WP1 will focus on the synthesis of the nanomaterials and the uploading of the therapeutics. WP2 will take the best nanoparticles and focus more on the evaluation of the permeation and efficacy of the formulations against NSCs. WP3 will focus on in vivo studies to evaluate the formulations developed to tackle the brain and to assess their toxicity. The project will train 14 ESRs in areas including organic and polymer chemistry, cell biology, pharmacology, neuroscience, nanobiotechnology and clinical sciences. The project will also provide a substantial training program in complementary skills, targeting both professional and personal development, and translation of research and entrepreneurship. The project brings together six academic partners, one hospital and two industrial teams as full partners, complemented by four associate partners, one of which is an industrial team, distributed over a total of seven European Union member states. The consortium brings together groups with a very interdisciplinary expertise ranging from nanoparticle synthesis and characterization, computational modeling, in vitro BBB models and BBB transport, neural stem cells, animal testing and clinical expertise.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NANOSTEM" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NANOSTEM" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.1.)

ORBITAL (2019)

Ocular Research By Integrated Training And Learning

Read More  

INSPIRE (2020)

INnovation in Safety Pharmacology for Integrated cardiovascular safety assessment to REduce adverse events and late stage drug attrition.

Read More  

MLFPM2018 (2019)

Machine Learning Frontiers in Precision Medicine

Read More